Autoantibody Signatures in Prostate Cancer

• Published in: The New England journal of medicine Vol. 353; no. 12; pp. 1224 - 1235
• Main Authors: Wang, Xiaoju, Yu, Jianjun, Sreekumar, Arun, Varambally, Sooryanarayana, Shen, Ronglai, Giacherio, Donald, Mehra, Rohit, Montie, James E, Pienta, Kenneth J, Sanda, Martin G, Kantoff, Philip W, Rubin, Mark A, Wei, John T, Ghosh, Debashis, Chinnaiyan, Arul M
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 22-09-2005
• Subjects: Aged; Aged, 80 and over; Autoantibodies - blood; Biological and medical sciences; Biomarkers - blood; Biomarkers, Tumor - blood; Case-Control Studies; Colleges & universities; General aspects; Humans; Logistic Models; Male; Medical sciences; Middle Aged; Nephrology. Urinary tract diseases; Peptide Library; Peptides - immunology; Prostate - immunology; Prostate cancer; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - immunology; Protein Array Analysis; Sensitivity and Specificity; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Autoimmunity; Medicine; Urinary system disease; Prostate disease; Antibody; Autoantibody; Malignant tumor; Male genital diseases; Prostate cancer
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa051931

This article describes a new method of detecting autoantibodies against prostate cancer antigens in the serum of patients with prostate cancer. The method could add information to the standard test for prostate-specific antigen.
This article describes a new method of detecting autoantibodies against prostate cancer antigens in the serum of patients with prostate cancer.
Limitations of the prostate-specific antigen (PSA) test for the early detection of prostate cancer
1
indicate the need for other means of screening for this neoplasm. The finding that patients with cancer produce autoantibodies against antigens in their tumors
2
–
7
suggests that such autoantibodies could have diagnostic and prognostic value.
4
,
5
,
8
–
10
For example, mutant forms of the p53 protein elicit anti-p53 antibodies in 30 to 40 percent of patients with various types of cancers.
11
Recently, we found that patients with prostate cancer produce antibodies against α-methylacyl-coenzyme A racemase,
12
an overexpressed protein in epithelial cells in prostate cancer.
13
–
15
This . . .